NEW YORK – The European Commission (EC) on Monday granted marketing authorization to AbbVie's Elahere (mirvetuximab soravtansine) as a new therapy option for previously treated patients with folate ...

The EC has approved Elahere for treating adult patients with folate receptor-alpha (FRα) positive, platinum-resistant and ...

AbbVie (ABBV) announced the European Commission, or EC, granted marketing authorization for Elahere for the treatment of adult patients with ...

The trial of the PanEcho software, presented at the American Heart Association (AHA) congress in Chicago, suggests that it ...

Allarity maintains a cash balance of $18.5 million, sufficient to advance and accelerate stenoparib's clinical development ...

The decision in Europe follows an approval granted by the US Food and Drug Administration (FDA) in March this year.

AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically ...

Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer and full approval earlier this year, was the key asset in AbbVie's $10.1 billion ...

AbbVie (ABBV) announced that the European Commission approved ELAHERE or mirvetuximab soravtansine for the treatment of adult ...

This is a news collection page for Canberra. Check this page for latest news headlines covering major stories, events from Canberra and surrounding ACT. Get breaking news faster than any other ...

Armata Pharmaceuticals, Inc. ("Armata" or the "Company"), a biotechnology company focused on high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat ...

Aon plc , a leading global professional services firm, has released its 2025 Global Medical Trend Rates Report. In Canada, the report forecasted the average medical trend rate for 2025 to be 7.4 ...